These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Building predictive ADMET models for early decisions in drug discovery. Penzotti JE; Landrum GA; Putta S Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148 [TBL] [Abstract][Full Text] [Related]
7. International Drug Discovery Science and Technology--BIT's Seventh Annual Congress. Bodovitz S IDrugs; 2010 Jan; 13(1):23-5. PubMed ID: 20024843 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in physicochemical and ADMET profiling in drug discovery. Wang J; Skolnik S Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823 [TBL] [Abstract][Full Text] [Related]
9. Advances and Progress in Drug Design - SMi's ninth annual meeting. Welchman R IDrugs; 2010 Apr; 13(4):239-42. PubMed ID: 20373252 [TBL] [Abstract][Full Text] [Related]
10. Improving compound quality through in vitro and in silico physicochemical profiling. van de Waterbeemd H Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820 [TBL] [Abstract][Full Text] [Related]
11. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience. Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652 [TBL] [Abstract][Full Text] [Related]
12. Applications of high-throughput ADME in drug discovery. Kassel DB Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334 [TBL] [Abstract][Full Text] [Related]
13. Biomarkers in Clinical Trials--SMi Conference. 23-24 September 2009, London, UK. Walker G IDrugs; 2009 Nov; 12(11):673-4. PubMed ID: 19844848 [TBL] [Abstract][Full Text] [Related]
14. The role of natural products in drug discovery and development in the new millennium. Harvey A IDrugs; 2010 Feb; 13(2):70-2. PubMed ID: 20127553 [TBL] [Abstract][Full Text] [Related]
15. The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries. Modi S; Hughes M; Garrow A; White A Drug Discov Today; 2012 Feb; 17(3-4):135-42. PubMed ID: 22063083 [TBL] [Abstract][Full Text] [Related]
16. Evolving molecules using multi-objective optimization: applying to ADME/Tox. Ekins S; Honeycutt JD; Metz JT Drug Discov Today; 2010 Jun; 15(11-12):451-60. PubMed ID: 20438859 [TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization. Peters SA; Ungell AL; Dolgos H Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647 [TBL] [Abstract][Full Text] [Related]
18. SMi's Conducting Clinical Trials in Europe. Jago C IDrugs; 2009 Dec; 12(12):754-9. PubMed ID: 19943216 [TBL] [Abstract][Full Text] [Related]
19. Predicting drug-drug interactions in drug discovery: where are we now and where are we going? Hutzler M; Messing DM; Wienkers LC Curr Opin Drug Discov Devel; 2005 Jan; 8(1):51-8. PubMed ID: 15679172 [TBL] [Abstract][Full Text] [Related]
20. In silico prediction of ADME properties: are we making progress? Beresford AP; Segall M; Tarbit MH Curr Opin Drug Discov Devel; 2004 Jan; 7(1):36-42. PubMed ID: 14982146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]